These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23898556)

  • 1. The endocannabinoid system and its role in the pathogenesis and treatment of cardiovascular disturbances in cirrhosis.
    Măries L; Manitiu I
    Acta Gastroenterol Belg; 2013 Jun; 76(2):195-9. PubMed ID: 23898556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
    Baldassarre M; Giannone FA; Napoli L; Tovoli A; Ricci CS; Tufoni M; Caraceni P
    Liver Int; 2013 Oct; 33(9):1298-308. PubMed ID: 23890208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile acids and cardiovascular function in cirrhosis.
    Voiosu A; Wiese S; Voiosu T; Bendtsen F; Møller S
    Liver Int; 2017 Oct; 37(10):1420-1430. PubMed ID: 28222247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy.
    Yang YY; Lin HC
    J Chin Med Assoc; 2012 Dec; 75(12):619-23. PubMed ID: 23245476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.
    Mallat A; Lotersztajn S
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G9-G12. PubMed ID: 17975129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis.
    Siegmund SV; Schwabe RF
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G357-62. PubMed ID: 18006606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on cirrhotic cardiomyopathy.
    Møller S; Danielsen KV; Wiese S; Hove JD; Bendtsen F
    Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):497-505. PubMed ID: 30802157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the endocannabinoid system in liver diseases.
    Caraceni P; Domenicali M; Giannone F; Bernardi M
    Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):65-77. PubMed ID: 19285261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cirrhotic cardiomyopathy.
    Ruiz-del-Árbol L; Serradilla R
    World J Gastroenterol; 2015 Nov; 21(41):11502-21. PubMed ID: 26556983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
    Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
    J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cirrhotic cardiomyopathy: a cardiologist's perspective.
    Gassanov N; Caglayan E; Semmo N; Massenkeil G; Er F
    World J Gastroenterol; 2014 Nov; 20(42):15492-8. PubMed ID: 25400434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cirrhotic cardiomyopathy: a specific entity].
    Brondex A; Arlès F; Lipovac AS; Richecoeur M; Bronstein JA
    Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):99-104. PubMed ID: 22115174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of extrahepatic vasodilation in portal hypertension.
    Hennenberg M; Trebicka J; Sauerbruch T; Heller J
    Gut; 2008 Sep; 57(9):1300-14. PubMed ID: 18445644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system and liver diseases.
    Caraceni P; Domenicali M; Bernardi M
    J Neuroendocrinol; 2008 May; 20 Suppl 1():47-52. PubMed ID: 18426499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cirrhotic cardiomyopathy].
    Kim MY; Baik SK
    Korean J Hepatol; 2007 Mar; 13(1):20-6. PubMed ID: 17380071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in cirrhotic cardiomyopathy.
    Karagiannakis DS; Papatheodoridis G; Vlachogiannakos J
    Dig Dis Sci; 2015 May; 60(5):1141-51. PubMed ID: 25404411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of the pharmacological antagonism of the endocannabinoid receptors on the sodium balance in liver cirrhosis].
    Montanari G; Santi L; Giannone F; Morieri ML; Domenicali M; Caraceni P; Bernardi M
    Recenti Prog Med; 2011 Feb; 102(2):75-81. PubMed ID: 21513122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cirrhotic cardiomyopathy].
    Osipenko MF; Bikbulatova EA
    Klin Med (Mosk); 2007; 85(9):80-3. PubMed ID: 18038577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cirrhotic cardiomyopathy: an endocannabinoid connection?
    Pacher P; Bátkai S; Kunos G
    Br J Pharmacol; 2005 Oct; 146(3):313-4. PubMed ID: 16025137
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac involvement in liver cirrhosis.
    Gatta A; Merkel C; Sacerdoti D; Angeli P
    Ann Ital Med Int; 1993; 8(4):244-7. PubMed ID: 8161481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.